Your browser doesn't support javascript.
loading
The prevalence and year lived with disability of atopic dermatitis in China: Findings from the global burden of disease study 2019.
Dong, Wen-Lan; An, Jing; Yu, Miao; Yin, Peng; Xu, Ting-Ling; Liu, Bo; Zuberbier, Torsten; Zhao, Zuo-Tao; Zhou, Mai-Geng.
Afiliação
  • Dong WL; National Center for Chronic and Noncommunicable Disease Control and Prevention, Beijing 100050, People's Republic of China.
  • An J; Beijing Xicheng District Maternal and Child Health Hospital, Beijing 100054, People's Republic of China.
  • Yu M; Peking University First Hospital, Beijing 100034, People's Republic of China.
  • Yin P; National Center for Chronic and Noncommunicable Disease Control and Prevention, Beijing 100050, People's Republic of China.
  • Xu TL; National Center for Chronic and Noncommunicable Disease Control and Prevention, Beijing 100050, People's Republic of China.
  • Liu B; Peking University First Hospital, Beijing 100034, People's Republic of China.
  • Zuberbier T; Charité - Universitätsmedizin Berlin Hindenburgdamm 30, Haus II D-10117, Berlin, UK.
  • Zhao ZT; Peking University First Hospital, Beijing 100034, People's Republic of China.
  • Zhou MG; National Center for Chronic and Noncommunicable Disease Control and Prevention, Beijing 100050, People's Republic of China.
World Allergy Organ J ; 14(11): 100604, 2021 Nov.
Article em En | MEDLINE | ID: mdl-34820052
ABSTRACT

BACKGROUND:

Atopic dermatitis (AD) is a chronic disease with growing prevalence and has become a global public health problem. However, little is known about the burden caused by AD in China.

OBJECTIVE:

To access the prevalence and burden of AD in China.

METHODS:

We estimated the prevalence and year lived with disability (YLD) of AD in China, by different age and sex groups. We also compared the burden of AD in China with other countries in the Group of Twenty (G20). We analyzed the changes in the number of AD patients and their YLDs by cause decomposition from 1990 to 2019.

RESULTS:

AD was the twenty-fourth leading cause of the burden of 369 diseases in China in 2019. From 1990 to 2019, the age-standardized prevalence and YLD rate of AD in China increased by 1.04% and 1.43% respectively, which were the second and the largest increase among the G20 and both higher than the global average (-4.29% and -4.14%). The number of patients with AD increased by 25.65%, of which 20.16% was due to population growth, 3.85% due to population aging, and 1.64% due to age-specific prevalence. Both the prevalence and YLD rate of AD were higher in 1 to 4 year-olds and 95+ years age group. Before the age of 10, the prevalence and YLD rate of AD in males were higher than those in females, while there was a marked sex shift at the ages of 10 to 14.

CONCLUSION:

AD is a serious public health problem in China. Substantial variations exist in burden due to AD between male and female, and in age groups. Considering these findings will be important for developing preventive strategies and treatments to reduce the burden of AD.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prevalence_studies / Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prevalence_studies / Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article